“Yes we can,” as incoming president Barack Obama famously declared in his presidential victory speech. Head down the road to The Capitol and we’ll need to modify that to, “Yes, we might,” as lawmakers in Congress debate an $825 billion economic stimulus package.

With stores tripping over themselves to offer steep holiday season discounts, their efforts were largely in vain, as many consumers simply weren’t financially able to take full advantage. Even the beast that is Wal-Mart (NYSE: WMT) struggled to make much headway. As we reported yesterday, Thomson-Reuters projected a 2.8% same-store sales rise for the firm in December. But the actual results proved otherwise.

Marc Lichtenfeld is convinced we’ll soon have a once-in-a-generation opportunity to buy assets at irrationally low prices. Market conditions are extreme at the moment. But this will pass, eventually, and stocks will recover strongly. Marc gives six reasons why it will soon be time to load up on stocks again.

Ecuador, Ghana and Tunisia are the only equity markets up in 2008. But Marc Lichtenfeld says there are still profit opportunities closer to home. Many undervalued US stocks are due a rebound in 2009. Marc picks seven proven survivors that are among the biggest and best in their fields. He also selects two small caps that are well place to lead a market recovery next year.

This holiday season will be a “bloodbath” for retailers, according to Marc Lichtenfeld. But there are still some companies that will dodge the downtrend. Marc says Kohl’s (NYSE:KSS), Wal-Mart (NYSE:WMT) and Dollar Tree (Nasdaq:DLTR) are well placed to weather the crisis. And they could even benefit from the demise of the competition.

Marc Lichtenfeld at The Smart Profits Report says he’s found an “immense” investment opportunity in a small-cap biotech firm.

There are three entry points in biotech stocks. They are: The first stages of research for a new drug; the initial human trial phases; and immediately before the drug is FDA approved. The later the entry point, the safer the investment.

The stock Marc has his eye on is a late-stage company. It is finishing Phase III trials for a unique cancer treatment drug which, if successful, will corner an entire market.

Investing in biotech stocks can be incredibly rewarding, financially and personally, says Marc Lichtenfeld writing in Investment U. However, timing is crucial to success. Here, Marc walks investors through the three phases of the drug development process…

Former Soviet republic Georgia is in turmoil. Eyewitness say villages are being burned and looted as Russian tanks and soldiers advance from the breakaway province of South Ossetia.

But the markets remain relatively unmoved by the fighting in the Caucasus. In particular, oil and gold remain low.

That’s because markets do not respond to macro events, says Marc Licthenfeld in The Smart Profits Report. It’s just the opposite: The market is an excellent predictor of economies and world events, with the economy typically following the market’s lead six to nine months later. More from Marc…

Blindly following stock tips from Wall Street analysts is a bad idea, says Marc Lichtenfeld in The Smart Profits Report. For most investment bankers, drumming up business and trading commissions is more of a priority than getting every forecast right. Finding a quality company that Wall Street ignores is a surefire way to book considerable profits. More from Marc…

What They’re Saying About The Financial Sector Sounds Nice… As I was running to catch my early morning flight on Saturday, I grabbed a copy of the New York Times and Barron’s. I looked at the Barron’s cover and figured that I must not have gotten enough sleep and was still in dreamland.